News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) New Data on Investigational Agent Belatacept in Kidney Transplant Recipients to be Presented at 2011 American Transplant Congress


4/25/2011 8:30:27 AM

PRINCETON, N.J.--(BUSINESS WIRE)--New data on belatacept, an investigational selective T cell costimulation blocker being studied for use in renal transplantation by Bristol-Myers Squibb Company (NYSE:BMY), will be presented at the American Transplant Congress April 30 – May 4, 2011 in Philadelphia. In total, 21 abstracts from company-sponsored studies will be presented during the congress, including seven oral presentations related to kidney transplantation. The data being presented highlights the broad clinical program for belatacept, a key compound supporting Bristol-Myers Squibb’s strategy to discover and develop targeted therapies for serious diseases.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES